ENDOCARE CRYCARE CRYOSURGICAL SYSTEM

K963826 · Endocare, Inc. · GEH · Dec 18, 1996 · General, Plastic Surgery

Device Facts

Record IDK963826
Device NameENDOCARE CRYCARE CRYOSURGICAL SYSTEM
ApplicantEndocare, Inc.
Product CodeGEH · General, Plastic Surgery
Decision DateDec 18, 1996
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.4350
Device ClassClass 2
AttributesTherapeutic

Intended Use

The ENDOcare CRYOcare™ Cryotherapy System is designed for use in general surgery, dermatology, neurology, thoracic surgery, ENT, gynecology, oncology, proctology and urology for the ablation of tissue, including liver metastases, skin lesions, warts and removal of prostate tissue.

Device Story

ENDOcare CRYOcare™ Cryosurgical System; cryosurgical control unit with 2, 5, or 8-probe configurations; utilizes single-use cryoprobes to ablate tissue via extreme cold. System monitors tissue temperature via independent T-type needle thermocouple inputs. Operated by clinicians in surgical settings; powered by 110 VAC. Cryoprobes feature small active cooling zones at tips; constructed of surgical stainless steel; no moving parts. System provides controlled cooling capacity for effective tissue destruction. Clinicians use temperature monitoring to guide ablation duration and extent, facilitating targeted tissue removal while sparing surrounding structures.

Clinical Evidence

Bench testing only. Sterilization validation conducted per ANSI/AAMI/ISO 11135-1994 using ethylene oxide (EtO) overkill method to achieve SAL 10^-6. EtO residual limits established at 25 ppm for ethylene oxide, 25 ppm for ethylene chlorohydrin, and 250 ppm for ethylene glycol.

Technological Characteristics

System includes control unit and single-use cryoprobes. Probes made of surgical stainless steel. Sensing: T-type needle thermocouples. Energy: Cryogenic cooling. Power: 110 VAC. Sterilization: Ethylene Oxide (EtO) per ANSI/AAMI/ISO 11135-1994. Packaging: Plastic film and coated paper sterile barrier.

Indications for Use

Indicated for tissue ablation in general surgery, dermatology, neurology, thoracic surgery, ENT, gynecology, oncology, proctology, and urology, including liver metastases, skin lesions, warts, and prostate tissue removal.

Regulatory Classification

Identification

(1) Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. (2) Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold. (3) Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0} Section 2.0 - SMDA 1990 Requirements K963926 2.1 510(K) Summary DEC 18 1996 ## Device Description The current ENDOcare CRYOcare™ Cryosurgical System is a cryosurgical system that consists of a control unit and eight cryoprobes. The Cryosurgical System also incorporates independent thermocouple inputs to monitor temperatures from standard T-type needle thermocouples. The system is compact and operates off of standard 110 VAC wall power. The control units for the 2 and 5-probe models will have the same performance characteristics as the 8-probe model. The only difference will be in the outer case which will be smaller and more cost effective to meet the needs of different customers. At the heart of the ENDOcare CRYOcare™ Cryosurgical System is the Cryoprobe. The Cryoprobes limit the extreme cold zone to a small active area at the tip, which results in an overall more efficient surgical tool. The probes are supplied sterile and individually packaged. The probes used for the 2-probe and 5-probe output configurations are exactly the same as those for the 8-probe output configuration. The ENDOcare Cryoprobe is a single use cryostat. Cryostats have been used as refrigerant devices for the past one hundred years. The Cryoprobe has no moving parts and is made of standard surgical stainless steel. The ENDOcare Cryoprobe is small enough in diameter to used medically, yet generates enough cooling capacity to effectively ablate tissue. ## Substantial Equivalence Support The ENDOcare CRYOcare™ Cryotherapy System is designed for use in general surgery, dermatology, neurology, thoracic surgery, ENT, gynecology, oncology, proctology and urology for the ablation of tissue, including liver metastases, skin lesions, warts and removal of prostate tissue. The current ENDOcare CRYOcare™ Cryotherapy System includes an 8-probe output model which was originally determined to be substantially equivalent on January 19, 1995 (reference K942299). The system will also be marketed in smaller, more cost effective models that utilize less probes. In addition to the 8-probe output model, ENDOcare will market a 2-probe output and a 5-probe output model. The additional models are substantially equivalent to the previously cleared device. The performance characteristics and technology will remain the same. The primary difference is that the number of probes will be less and the control units will be smaller to meet the different needs of customers. ## Sterilization Methodology The following sterilization information is applicable to the Cryoprobes only. Sterilization validation will be conducted utilizing an overkill method based on the recommendations in the current American Association for the Advancement of Medical Instrumentation (ANSI/AAMI/ISO 11135-1994) Guideline for Industrial Ethylene Oxide. {1} Sterilization of Medical Devices. A minimum Sterility Assurance Level (SAL) of $10^{-6}$ will be achieved. Sterile barrier packaging will consist of standard disposable medical device packaging containing a plastic film and a coated paper side. This is the same sterile barrier packaging that is used with the 8-Probe model. Maximum levels of EtO residuals will not exceed: - 25 ppm for ethylene oxide - 25 ppm for ethylene chlorohydrin - 250 ppm for ethylene glycol
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%